{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:19:06Z","timestamp":1790893146079,"version":"4.1.0"},"reference-count":40,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T00:00:00Z","timestamp":1678320000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Pruritus is a frequent symptom experienced by patients with myeloproliferative neoplasms (MPN). Aquagenic pruritus (AP) is the most common type. The Myeloproliferative Neoplasm\u2010Symptom Assessment Form Total Symptom Score (MPN\u2010SAF TSS) self\u2010report questionnaires were distributed to MPN patients before consultations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>The aim of this study was to assess clinical incidence (phenotypical evolution and response to treatment) of pruritus, especially AP, in MPN patients during their follow\u2010ups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p>We collected 1444 questionnaires from 504 patients [54.4% essential thrombocythaemia (ET) patients, 37.7% polycythaemia vera (PV) patients, and 7.9% primary myelofibrosis (PMF) patients].<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Pruritus was reported by 49.8% of the patients, including 44.6% of AP patients, regardless of type of MPN or driver mutations. Patients suffering from pruritus were more symptomatic and had a higher rate of evolution into myelofibrosis\/acute myeloid leukaemia (19.5% vs. 9.1%, OR\u00a0=\u00a02.42 [1.39; 4.32],<jats:italic>p<\/jats:italic>\u00a0=\u20090.0009) than MPN patients without pruritus. Patients with AP had the highest pruritus intensity values (<jats:italic>p<\/jats:italic>\u00a0=\u20090.008) and a higher rate of evolution (25.9% vs. 14.4%,<jats:italic>p<\/jats:italic>\u00a0=\u20090.025, OR\u00a0=\u00a02.07) than patients with non\u2010AP. Disappearance of pruritus was observed in only 16.7% of AP cases, compared to 31.7% of cases with other types of pruritus (<jats:italic>p<\/jats:italic>\u00a0&lt;\u20090.0001). Ruxolitinib and hydroxyurea were the most effective drugs to reduce AP intensity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In this study, we demonstrate the global incidence of pruritus across all MPN. Pruritus, especially AP, which is a major constitutional symptom observed in MPN, should be assessed in all MPN patients due to higher symptom burden and higher risk of evolution.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.18990","type":"journal-article","created":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T17:12:08Z","timestamp":1676999528000},"page":"1175-1183","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Differences between aquagenic and non\u2010aquagenic pruritus in myeloproliferative neoplasms: An observational study of 500 patients"],"prefix":"10.1111","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0158-2850","authenticated-orcid":false,"given":"Christelle","family":"Le\u00a0Gall\u2010Ianotto","sequence":"first","affiliation":[{"name":"Service de Dermatologie CHRU de Brest Brest France"},{"name":"Univ Brest, LIEN, CHRU Brest Brest France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne\u2010Sophie","family":"Ficheux","sequence":"additional","affiliation":[{"name":"Service de Dermatologie CHRU de Brest Brest France"},{"name":"Univ Brest, LIEN, CHRU Brest Brest France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Lippert","sequence":"additional","affiliation":[{"name":"Laboratoire d'H\u00e9matologie CHRU de Brest Brest France"},{"name":"France Intergroupe des N\u00e9oplasies My\u00e9loprolif\u00e9ratives (FIM) Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Herbreteau","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie et d'H\u00e9mostase Clinique Institut de Canc\u00e9ro\u2010H\u00e9matologie, CHRU de Brest Brest France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Rio","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie et d'H\u00e9mostase Clinique Institut de Canc\u00e9ro\u2010H\u00e9matologie, CHRU de Brest Brest France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Pan\u2010Petesch","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie et d'H\u00e9mostase Clinique Institut de Canc\u00e9ro\u2010H\u00e9matologie, CHRU de Brest Brest France"},{"name":"INSERM, Univ Brest CHRU Brest, UMR 1304, GETBO Brest France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8088-7059","authenticated-orcid":false,"given":"Laurent","family":"Misery","sequence":"additional","affiliation":[{"name":"Service de Dermatologie CHRU de Brest Brest France"},{"name":"Univ Brest, LIEN, CHRU Brest Brest France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Christophe","family":"Ianotto","sequence":"additional","affiliation":[{"name":"France Intergroupe des N\u00e9oplasies My\u00e9loprolif\u00e9ratives (FIM) Paris France"},{"name":"Service d'H\u00e9matologie et d'H\u00e9mostase Clinique Institut de Canc\u00e9ro\u2010H\u00e9matologie, CHRU de Brest Brest France"},{"name":"INSERM, Univ Brest CHRU Brest, UMR 1304, GETBO Brest France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,3,9]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-579136"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0077-1"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.3863"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-328955"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22365"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.05.020"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.06.001"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2020.1780755"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1208814"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23474"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14809"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14588"},{"issue":"10","key":"e_1_2_12_15_1","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1610-0387.2010.07463.x","article-title":"Aquagenic pruritus: associated diseases and clinical pruritus characteristics","volume":"8","author":"Heitkemper T","year":"2010","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16117"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/ced.13872"},{"issue":"1","key":"e_1_2_12_18_1","first-page":"76","article-title":"Prurit aquag\u00e9nique [Aquagenic pruritus]","volume":"126","author":"Bayrou O","year":"1999","journal-title":"Ann Dermatol Venereol"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.03161.x"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21156"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2906"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21645"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-099184"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-12-064287"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110556"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409002"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000646"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25700"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24976"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2010.02334.x"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1400"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-021-05864-8"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/4790810"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.163"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18071485"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/102476"},{"key":"e_1_2_12_37_1","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/145293","article-title":"Pathogenesis of myeloproliferative neoplasms: role and mechanisms of chronic inflammation","volume":"2015","author":"Hermouet S","year":"2015","journal-title":"Mediators Inflamm"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2017.12.003"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2012.07.003"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-09-179416"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S287944"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.18990","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.18990","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.18990","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T20:19:46Z","timestamp":1728937186000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.18990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,9]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1111\/jdv.18990"],"URL":"https:\/\/doi.org\/10.1111\/jdv.18990","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,9]]},"assertion":[{"value":"2022-07-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}